Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients

Molecular Diagnosis and Therapy

Volumn 19, Issue 3, 2015, Pages 179-190

  Toraih, Eman A ^a   Mohammed, Eman A ^a   Farrag, Sherif ^a   Ramsis, Nevene ^a   Hosny, Somaya ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 21; MICRORNA; MIRN21 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EGYPTIAN; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; EGYPT; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UPREGULATION;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EGYPT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; UP-REGULATION;

EID: 84931569879     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-015-0143-6     Document Type: Article

References (85)

1. Wang K, Yuan Y, Cho J, McClarty S, Baxter D, Galas D. Comparing the microRNA spectrum between serum and plasma. PLoS One. 2012;7(7):e41561.
2. Hussein O, Mosbah M, Farouk O, Farag K, El-Saed A, Arafa M, Abdallah A. Hormone receptors and age distribution in breast cancer patients at a university hospital in Northern Egypt. Breast Cancer (Auckl). 2013;7:51–7.
3. Yu D, Qing-Guo L, Xi-Wei D, Yi-Tao D. Circulating MicroRNAs: potential biomarkers for cancer. Int J Mol Sci. 2011;12:2055–63.
4. Kishore A, Jana B, Jana P, Martin P. Review article novel insights into miRNA in lung and heart inflammatory diseases. Mediat Inflamm. 2014;2014:27.
5. Pan F, Mao H, Deng L, Guangchao L, Geng P. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol. 2014;7(9):5622–33.
6. Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Samaei N. Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One. 2013;8(9):e73009.
7. Yin Y, Jun L, Shujie C, Tianhua Z, Jianmin S. MicroRNAs as diagnostic biomarkers in gastric cancer. Int J Mol Sci. 2012;13:12544–55.
8. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H, Ren X. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene. 2014;533(1):389–97.
9. Corcoran C, Anne M, Duffy J, Crown J, O’Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem. 2011;57(1):18–32.
10. Godfrey A, Zongli X, Clarice R, Robert C, Paul A, Dale P, Jack A. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 2013;15:R42–51.
11. Ng E, Li R, Shin V, Jin H, Leung C, Ma E, Pang R, Kwong A. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8(1):e53141.
12. Kosaka N, Yusuke Y, Keitaro H, Naoomi T, Takeshi K, Takahiro O. Trash or Treasure: extracellular microRNAs and cell-to-cell communication. Front Genet. 2013;4:173.
13. Zhou X, Wang X, Huang Z, Wang J, Zhu W, Shu Y, Liu P. Prognostic value of miR-21 in various cancers: an updating meta-analysis. PLoS One. 2014;9(7):e102413.
14. Si H, Xiaoming S, Yingjian C, Yuan C, Shimin C, Huanchun W. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Chengjin Hu J Cancer Res Clin Oncol. 2013;139:223–9.
15. Evans D, Howell H. Breast cancer risk-assessment models. Breast Cancer Res. 2007;9:213–21.
16. John S, Consuelo A, Clara M, Neal O, Irma R, Jose R, Andrew G, Barbara A, Karen L, Reza P. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005;18:1067–78.
17. Singletary S, James L. Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin. 2006;56:37–47.
18. Aoife J, Nicola M, Amanda D, Roisin E, Pamela A, Graham B, Michael J. MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11(3):R27–45.
19. Homa O, Daigo Y, Yoshiko U, Noriko S, Masanori Y, Kanji T, Yasuo K. Prognostic factors in breast cancer: the value of the Nottingham prognostic index for patients treated in a single institution. Surg Today. 2005;35:907–11.
20. Guerra I, Algorta J, Díaz de Otazu R, Pelayo A, Fariña J. Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol. 2003;56(6):323–7.
21. Kataja V, Castiglione M, On behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(4):iv10–4. doi:10.1093/annonc/mdp114.
22. Heneghan H, Miller N, Lowery A, Karl J, Newell J, Michael J. Circulatory microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499–505.
23. Schmittgen D, Eun J, Jinmai J, Anasuya S, Liuqing Y, Terry S, Caifu C. Real-time PCR quantification of precursor and mature microRNA. Methods. 2008;44(1):31–8.
24. Li-Xu Y, Xiu-Fang H, Qiong S, Deng L, Wu Q, Zeng Y, Shao J. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348–60.
25. Huang G, Zhang X, Guo G, Huang K, Yang K, Shen X, You J, Hu X. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009;21(3):673–9.
26. Heneghan H, Miller N, Lowery A, Kerin M. MicroRNAs as novel biomarkers for breast cancer. J Oncol. 2010;2010:950201–8.
27. Wan G, Qing E, Heng-Phon T. High-performance quantification of mature microRNAs by real-time RT-PCR using deoxyuridine-incorporated oligonucleotides and hemi-nested primers. RNA. 2010;16:1436–45.
28. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012;257(4):897–904.
29. Wu Q, Lu Z, Li H, Lu J, Guo L. Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol. 2011;2011:597145–52.
30. Hafez M, Hassan Z, Abdel Rahman N, Ayman A, Salem S, Sayed M, Al Shabanah O. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev. 2012;13:591–8.
31. Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.
32. Leidner R, Li L, Thompson C. Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One. 2013;8(3):e57841.
33. Ali S, Khaldoun A, Wei C, Philip A, Fazlul H. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res. 2011;3(1):28–47.
34. Li B, Yong-liang Z, Gang G, Wei L, Na L, Bin T, Kai-yun L, Bin X. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7(7):e41629.
35. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29:4781–8.
36. Hsu C, Lin P, Wang Y, Chen Z, Lin S, Yang M. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol. 2012;33:1933–42.
37. Lawrie C, Gal S, Dunlop H, Pushkaran B, Harris A. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–5.
38. Xu X, Jian C, Zhou L, Jian-Ping C. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 2012;4(2):339–45.
39. He H, Jazdzewski K, Li W, Liyanarachchi S, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci. 2005;102(52):19075–80.
40. Guan P, Zhihua Y, Xuelian L, Wei W, Baosen Z. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012;31(1):54.
41. Sapre N, Selth L. Circulating microRNAs as biomarkers of prostate cancer: the state of play. Prostate Cancer. 2013;2013:1–10.
42. Xiao-chun W, Wang W, Zhang Z, Zhao J, Tan X, Luo J-C. Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. Radiat Oncol. 2013;8:146.
43. Li S, Yang X, Yang J, Zhen J, Zhang D. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis. Clin Exp Med. 2014; 1–7. doi:10.1007/s10238-014-0332-3.
44. Cui Z, Lin D, Song W, Chen M, Li D. Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study. Tumor Biol. 2015;36(2):829–39. doi:10.1007/s13277-014-2700-8.
45. Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013;25(6):743–8.
46. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano A, Hoon D. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91.
47. Sun Y, Wang M, Lin G, Sun S, Li X, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012;7(10):e47003.
48. Zhao H, Jie S, Leonard M, Dan W, Christine B, Song L. A pilot study of circulating mirnas as potential biomarkers of early stage breast cancer. PLoS One. 2010;5(10):e13735.
49. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011;91(3):827–87.
50. Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets. 2010;11:926–35.
51. Sempere L, Christensen M, Silahtaroglu A. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612–20.
52. Que R, Guoping D, Jionghuang C, Liping C. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol. 2013;11:219–27.
53. Glowacki F, Savary G, Gnemmi V, Buob D, Van der H. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One. 2013;8(2):e58014.
54. Toiyama Y, Masanobu T, Keun H, Takeshi N, Koji T, Yasuhiro I, Ajay G. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59.
55. Zeng Z, Wang J, Zhao L, Hu P, Zhang H. Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One. 2013;8(9):e73278.
56. Shen L, Wan Z, Ma Y, Wu L, Liu F, Zang H, Xin S. The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers. Tumor Biol. 2015;36(3):1993–2005.
57. Heneghan H, Nicolamiller R, Johnnewell M. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15(7):673–82.
58. Qi P, S-q Cheng, Wang H, Li N, Y-f Chen. Serum microRNAs as biomarkers for hepatocellular carcinoma in chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6(12):e28486.
59. Palmero E, Silvana G, Marcelo C, Naiara C, Ismael D, Andre L, Marcia M. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol. 2011;34(3):363–70.
60. Volinia S, Marco G, Timothy F, Jeff P, Kay H, Carlo M. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. PNAS. 2012;109(8):3024–9.
61. Bianchi F, Nicassio F, Marzi M, Belloni E, Dallolio V, Bernard L. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3:495–503.
62. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce C, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci. 2011;108:3713–8.
63. Ramshankar V, Krishnamurthy A. Lung cancer detection by screening—presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pacific J Cancer Prev. 2013;14(4):2167–72.
64. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116. doi:10.3389/fgene.2013.00116.
65. Lee J, Zhao T, Clifton-Bligh R, Robinson G, Sidhu B. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013. doi:10.1002/cncr.28254.
66. Liu C, Kao S, Tu H, Tsai M, Chang K. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16:360–4.
67. Tsujiura M, Ichikawa D, Komatsu S, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102(7):1174–9.
68. Turchinovich A, Ludmila W, Anne L, Burwinke B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;2011:1–11.
69. Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS One. 2013;8(10):e76729.
70. Hirko K, Amr S, Ahmed H, Ibrahim A, Mohamed R, Mousumi B, Joe B, Robert M, Merajver S. Trends in breast cancer incidence rates by age and stage at diagnosis in Gharbiah, Egypt, over 10 Years (1999–2008). J Cancer Epidemiol. 2013;2013:916394.
71. Russo I, Russo J. Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia. 2011;16(3):221–33.
72. Walter B, Gómez-Macias G, Valera V, Sobel M, Merino M. MiR-21 expression in pregnancy-associated breast cancer: a possible marker of poor prognosis. J Cancer. 2011;2:67–75.
73. Tazzite A, Hassan J, Kamal S, Abdellatif B, Sellama N. Relationship between family history of breast cancer and clinicopathological features in Moroccan patients. Ethiop J Health Sci. 2013;23(2):150–7.
74. Bhat-Nakshatri P, Wang G, Collins N, Thomson M, Geistlinger T, Carroll J, Brown M, Hammond S, Srour E, Liu Y, Nakshatri H. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009;37(14):4850–61.
75. Wickramasinghe N, Manavalan T, Dougherty S, Riggs K, Li Y, Klinge C. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009;37(8):2584–2595.
76. Huang T, Fangting W, Allison B, Dai H, Yin-Yuan M, Andrei G, Michael T. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem. 2009;284:18515–24.
77. Findlay J. MicroRNAs and breast cancer. Open Cancer J. 2010;3:55–61.
78. Duygu S, Mark T, Charles S. MiR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009;37:918–25.
79. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. Biol Chem. 2011;286(21):19127–37.
80. Wang W, Luo Y-P. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B. 2015;16(1):18–31.
81. Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF. Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer. 2015;7:59.
82. Zhang H, Chen X. Serum/plasma microRNAs as biomarkers for lung cancer. Chin J Lung Cancer. 2012;15(1):52–5.
83. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012;59(4):467–74.
84. Komatsu S, Ichikawa D, Tsujiura M, Konishi H, Okamoto K, Otsuji E. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 2013;33(1):271–6.
85. Shi M, Liu D, Duan H, Shen B, Guo N. Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev. 2010;29:785–99.